LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Alan S. Wayne, MD
National Cancer Institute (NCI)
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Winship Cancer Institute of Emory University
Atlanta, Georgia, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
- Warren Grant Magnuson Clinical Center - Nci Clinical Trials Referral Office
Bethesda, Maryland, United States
- Doernbecher Children'S Hospital at Oregon Health & Science University
Portland, Oregon, United States
- St. Jude Children'S Research Hospital
Memphis, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2004
- Primary completion
- —
- Completion
- —
- Last update posted
- 30 Apr 2015
- Registered enrollment
- 40
- Registry id
- NCT00085150
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.